ChipDX

New York, United States Founded: 2008 • Age: 18 yrs Acquired By Signal Genetics
Oncology diagnostics and prognostics are provided using genomic data.
Request Access

About ChipDX

ChipDX is a company based in New York (United States) founded in 2008 was acquired by Signal Genetics in February 2012.. ChipDX operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Helix, among others.

  • Headquarter New York, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Signal Genetics

    (Feb 02, 2012)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ChipDX

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ChipDX

ChipDX has secured backing from 1 investor. Prominent investors backing the company include Signal Genetics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Microarray-based prognostic tests are provided for disease risk assessment.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ChipDX

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ChipDX

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Chipdx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ChipDX

ChipDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Helix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomic database for clinical research is provided.
domain founded_year HQ Location
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Chipdx

Frequently Asked Questions about ChipDX

When was ChipDX founded?

ChipDX was founded in 2008.

Where is ChipDX located?

ChipDX is headquartered in New York, United States. It is registered at New York, New York, United States.

What does ChipDX do?

Provider of oncology diagnostics and prognostics using genomic data. Its platform was a web-based database of gene expression patterns that could be compared against gene expression patterns of the patient sample for an accurate diagnosis. It had four products on the market CancerGeneDX for the characterization of metastasized or poorly-differentiated tumors, BreastGeneDX for the classification of tumor subtype and risk of recurrence, ColonGeneDX for the prognosis of stage II and III colon cancer patients, and LungGeneDX for the classification of early-stage patients of lung adenocarcinoma as high risk or low risk for metastasis and recurrence.

Who are the top competitors of ChipDX?

ChipDX's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.

Who are ChipDX's investors?

ChipDX has 1 investor. Key investors include Signal Genetics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available